Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Generic drug approvals boost pharma firms' global ambitions

By Liu Zhihua | China Daily | Updated: 2019-03-07 11:42
Share
Share - WeChat
Many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. [Photo/VCG]

Chinese pharmaceutical companies are strengthening their presence on the world stage with an increasing number of generic drug approvals from the United States, thanks to rising research and development capabilities and official support for innovation, industry insiders said.

According to statistics from the Healthcare Executive Institute, a leading healthcare industry think tank based in Beijing, as of Dec 24, 2018, Chinese pharmaceutical companies had received 77 generic drug approvals - known as abbreviated new drug applications or ANDAs - from the US Food and Drug Administration.

The number was 38 in 2017 and 22 in 2016. Before 2016, Chinese pharmaceutical companies had fewer than 15 ANDAs approved on average each year.

A recent example is a generic drug made by Qingdao Baheal Pharmaceutical Ltd, a holding subsidiary of Baheal Pharmaceutical Group headquartered in Beijing and Qingdao, Shandong province.

Its generic drug Nida, which is an extended-release tablet containing metformin, a medicine widely used to manage type-2 diabetes, was approved by the USFDA on Dec 27, 2018.

The company announced earlier that the first batch of the drug was about to be delivered to the US market.

The think tank said one reason behind the rise in approvals is that many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. Another reason is that once a generic drug receives US approval, it is automatically seen as having passed China's generic consistency evaluation requirements.

In 2016, the Chinese central authorities issued an opinion on "conducting consistency evaluations of the quality and efficacy of generic drugs", signaling a push for an industrywide overhaul of generic drug quality. Failure to pass the evaluation before the required deadline leads to revocation of the drug title's registration license or ineligibility for government tendering. Besides, if three titles of a generic drug have passed the evaluation, others will not be allowed for government tendering.

Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, added that the Chinese authorities' recent policies are very supportive of innovation and high-quality generic drug research and development, providing solid incentives for Chinese pharmaceutical companies to file more ANDAs.

"If a Chinese generic drug gains US approval, it is often fast tracked by Chinese authorities when it applies for domestic approval, giving it an advantage in the fiercely competitive domestic generic drug market," he said.

Shen Yaping, vice-president with Jiangsu Hengrui Medicine Co Ltd, a top Chinese pharmaceutical company listed in Shanghai, said the company now files new generic drug applications to domestic and US authorities for this reason.

"Going global and innovation are the two most important development strategies for our company, and now we feel encouraged, because a lot of government policies are inspiring to companies like us that want to expand overseas business," Shen said.

The overseas markets, especially the US, are large and alluring, yet in the past, Chinese pharmaceutical companies lacked the ability to expand overseas, he said, adding that as a number of first-tier Chinese pharmaceutical companies have succeeded in developing overseas business, others are trying to keep up with them.

His company and its subsidiary Shanghai Hengrui Pharmaceutical Co Ltd have received 16 ANDA approvals, according to its website.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 好吊妞乱淫欧美| 欧美性猛交xxxx乱大交| 国产婷婷综合在线视频| 99精品久久99久久久久久| 日本不卡免费新一二三区 | 日韩大片在线永久免费观看网站| 免费A级毛片无码A∨| 贵妇肉体销魂阅读| 国产精品成人久久久久久久| 一本加勒比hezyo东京re高清| 日韩在线电影网| 亚洲日本va在线观看| 精品国产v无码大片在线看| 国产在线播放网址| 18禁无遮挡无码网站免费 | 人人妻人人澡人人爽人人精品 | 精品美女在线观看| 国产成人精品亚洲一区| 91香蕉短视频| 娃娃脸中文字幕1080p| 久久久久亚洲av成人网人人软件 | 巨龙肉色透明水晶丝袜校花| 久久无码精品一区二区三区| 欧美日韩亚洲国产千人斩| 免费国产怡红院在线观看| 色欲色av免费观看| 国产成人精品高清不卡在线| 91福利视频一区| 女女同性一区二区三区四区| 丰满老**毛片| 日韩欧美在线播放视频| 亚洲国产成人久久笫一页| 狠狠色丁香婷婷综合潮喷| 又黄又刺激视频| 视频一区二区中文字幕| 好硬好湿好爽再深一点视频| 在线观看免费视频a| 国产精品久久久久影院嫩草| 国产久视频观看| 99无码精品二区在线视频| 成人妇女免费播放久久久|